New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone; ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone; ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone - capsule - active: ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch active: ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch - ziprasidone is also indicated as a monotherapy for the short term treatment of acute manic or mixed episodes associated with bipolar 1 disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 22.652mg equivalent to 20 mg ziprasidone - capsule - 20 mg - active: ziprasidone hydrochloride monohydrate 22.652mg equivalent to 20 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone - capsule - 40 mg - active: ziprasidone hydrochloride monohydrate 45.3mg equivalent to 40 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone - capsule - 60 mg - active: ziprasidone hydrochloride monohydrate 67.95mg equivalent to 60 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone - capsule - 80 mg - active: ziprasidone hydrochloride monohydrate 90.6mg equivalent to 80 mg ziprasidone excipient: gelatin lactose monohydrate magnesium stearate pregelatinised maize starch tekprint black sw-9008 - ziprasidone is indicated for the treatment of acute schizophrenia, and maintenance or continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.25mg (exclusive of 1.5% excess.);  ;   - tablet - 0.25 mg - active: alprazolam 0.25mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide [docusate sodium (85% ) with sodium benzoate [15%] lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 0.5mg (exclusive of 1.5% excess.);  ;   - tablet - 0.5 mg - active: alprazolam 0.5mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide docusate sodium erythrosine lactose monohydrate magnesium stearate maize starch microcrystalline cellulose sodium benzoate - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - alprazolam 1mg (exclusive of 1.5% excess.);  ;   - tablet - 1 mg - active: alprazolam 1mg (exclusive of 1.5% excess.)     excipient: colloidal silicon dioxide erythrosine indigo carmine docusate sodium (85%) with sodium benzoate (15%) lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - 1. anxiety states (anxiety neuroses). symptoms which occur in such patients include anxiety, tension, fear, insomnia, apprehension, restlessness, concentration difficulties, irritability and/or autonomic hyperactivity resulting in a variety of somatic complaints. 2. mixed anxiety-depression. symptoms of both anxiety and depression occur concurrently in such patients. 3. neurotic or reactive depression. such patients primarily exhibit a depressed mood or a pervasive loss of interest or pleasure. other characteristics include anxiety, appetite disturbances, changes in weight, cognitive disturbances, decreased energy, feeling of worthlessness or guilt, insomnia, somatic complaints, or thoughts of death or suicide. 4. anxiety states, mixed anxiety-depression, or neurotic depression associated with other diseases such as the chronic phase of alcohol withdrawal and functional or organic disease, particularly certain gastrointestinal, cardiovascular, or dermatological disorders.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - pregabalin 150mg - capsule - 150 mg - active: pregabalin 150mg excipient: colloidal silicon dioxide   gelatin   lactose monohydrate maize starch purified talc purified water   sodium laurilsulfate   tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   - lyrica (pregabalin) is indicated for the treatment of neuropathic pain in adults. lyrica (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - pregabalin 25mg - capsule - 25 mg - active: pregabalin 25mg excipient: colloidal silicon dioxide   gelatin   lactose monohydrate maize starch purified talc purified water   sodium laurilsulfate   tekprint black sw-9008 tekprint black sw-9009 titanium dioxide   - lyrica (pregabalin) is indicated for the treatment of neuropathic pain in adults. lyrica (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.